CN118021915A - Traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder - Google Patents
Traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder Download PDFInfo
- Publication number
- CN118021915A CN118021915A CN202410248079.3A CN202410248079A CN118021915A CN 118021915 A CN118021915 A CN 118021915A CN 202410248079 A CN202410248079 A CN 202410248079A CN 118021915 A CN118021915 A CN 118021915A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 24
- 230000000291 postprandial effect Effects 0.000 title claims abstract description 22
- 208000020685 sleep-wake disease Diseases 0.000 title claims abstract description 18
- 241000132012 Atractylodes Species 0.000 claims abstract description 14
- 241000202726 Bupleurum Species 0.000 claims abstract description 13
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 12
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 12
- 235000008397 ginger Nutrition 0.000 claims abstract description 12
- 235000005412 red sage Nutrition 0.000 claims abstract description 12
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 11
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 11
- 241001522129 Pinellia Species 0.000 claims abstract description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 10
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 10
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 10
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 10
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 7
- 241001127714 Amomum Species 0.000 claims abstract description 5
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 5
- 238000002360 preparation method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241000007126 Codonopsis pilosula Species 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 241001106477 Paeoniaceae Species 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 244000236658 Paeonia lactiflora Species 0.000 claims description 5
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 3
- 241000756943 Codonopsis Species 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 210000000952 spleen Anatomy 0.000 abstract description 23
- 208000024891 symptom Diseases 0.000 abstract description 22
- 230000001105 regulatory effect Effects 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 8
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 5
- 208000019901 Anxiety disease Diseases 0.000 abstract description 4
- 208000022925 sleep disturbance Diseases 0.000 abstract description 4
- 206010000059 abdominal discomfort Diseases 0.000 abstract description 3
- 230000036506 anxiety Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 43
- 208000035736 spondylodysplastic type Ehlers-Danlos syndrome Diseases 0.000 description 21
- 230000007812 deficiency Effects 0.000 description 14
- 235000019525 fullness Nutrition 0.000 description 10
- 201000006549 dyspepsia Diseases 0.000 description 8
- 206010000060 Abdominal distension Diseases 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 241000234314 Zingiber Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000003860 sleep quality Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- -1 compound [2- (dimethylamino) -2-phenylbutyl ] -3,4, 5-trimethoxybenzoate 4-methyl-2H-chromen-2-one-7-yl sulfate Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007661 gastrointestinal function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000003326 hypnotic agent Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229930192014 saikosaponin Natural products 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 206010059186 Early satiety Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 2
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000307676 Diploprion bifasciatum Species 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000010329 Xiangshaliujunzi decoction Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 230000005985 stomach dysfunction Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disturbance, which comprises the following components in parts by weight: 15-20 parts of bupleurum, 15-20 parts of bighead atractylodes rhizome, 20-25 parts of dangshen, 10-15 parts of immature bitter orange, 15-20 parts of white paeony root, 10-15 parts of dried orange peel, 10-15 parts of ginger processed pinellia tuber, 10-15 parts of red sage root, 10-15 parts of villous amomum fruit and 10-15 parts of honey-fried licorice root; the traditional Chinese medicine composition has the effects of soothing liver, strengthening spleen, regulating qi and regulating middle warmer, has good effects of improving symptoms such as epigastric pain and postprandial fullness, has good safety, can effectively relieve symptoms such as anxiety, depression and the like caused by gastrointestinal discomfort of patients, and has remarkable curative effects on postprandial discomfort syndrome accompanied with sleep disorder.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating senile postprandial discomfort syndrome accompanied with sleep disturbance.
Background
Postprandial malaise syndrome is a subtype of functional dyspepsia (Functional dyspepsia, FD), and roman iv classifies functional dyspepsia into upper abdominal pain syndrome (EPIGASTRIC PAIN syndrome, EPS) and postprandial malaise syndrome (Postprandial distress syndrome, PDS). PDS is a group of functional digestive system diseases with early satiety, postprandial satiety, inappetence and belching as main clinical characteristics, and mostly belongs to the category of "distention and fullness" in traditional Chinese medicine. Studies have shown that 4 out of every 5 FD patients on average are PDS, the incidence of which is positively correlated with FD, and the disease persists and has a great negative impact on the production and life of the patients. However, the pathogenesis of PDS is currently unknown, and prior studies have shown that it may be associated with a single or multifactorial cross-pathogenicity. The existing treatment is mainly started in the aspects of recovering gastrointestinal motility, protecting gastric mucosa and the like.
The Chinese medicine considers that the exogenous internal injury, diet, emotion and the like can cause the distention, and the Chinese medicine has various names such as ' no ', ' no diaphragmatic ', ' distention ', ' under the heart ', ' no fullness ' and the like in the yellow emperor's internal channel as follows: "prepared century, qi coordinating with Tianhuo, de Liu four politics, five changes and repair simultaneously, its qi level, its nature is along … … its disease" and "Su-Liu Yuan Zhengji's theory of six yuan" is: the "taiyin qi" refers to the accumulation of fluid in the body. "Zhang Zhongjing in Han Dynasty" discusses the pathogenesis of the distension and fullness syndrome in the treatise on typhoid treatise on the disease, the "treatise on the disease and pulse syndrome of Shang Han treatise on the disease and treating: the disease is caused by yin and adverse qi downward, and is considered to be the syndrome of distension and fullness due to the sun, and the syndrome of typhoid fever is caused by the misuse of the following method. The key of the PDS pathogenesis is spleen and stomach dysfunction, and the syndrome type distribution of the PDS patients is mainly spleen deficiency and qi stagnation, liver and stomach disharmony, spleen and stomach damp-heat syndrome, spleen and stomach deficiency-cold syndrome and cold-heat disharmony. In recent years, traditional Chinese medicines have shown unique advantages in the aspect of treating postprandial uncomfortable syndromes, have better effects, are mostly used for strengthening spleen and tonifying stomach, promoting qi circulation and resolving depression according to clinical symptoms such as early satiety, postprandial fullness feeling and the like, and are used together with other treatment methods aiming at pathogenesis.
Chinese patent document CN202180030284.7 discloses a novel compound [2- (dimethylamino) -2-phenylbutyl ] -3,4, 5-trimethoxybenzoate 4-methyl-2H-chromen-2-one-7-yl sulfate, relating to the use of the compound [2- (dimethylamino) -2-phenylbutyl ] -3,4, 5-trimethoxybenzoate 4-methyl-2H-chromen-2-one-7-yl sulfate for the treatment and prevention of functional gastrointestinal disorders.
Aiming at the functional dyspepsia patients, western medicine is often assisted in using medicines, but has the defects of short curative effect, easy recurrence and the like, and can not obtain satisfactory curative effect. There is therefore a need to propose new solutions in the field of traditional Chinese medicine.
Disclosure of Invention
In order to solve the defects existing in the prior art, the invention aims to provide the traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disturbance, which has good effects on improving symptoms such as epigastric pain, postprandial fullness and the like, has good safety, and can effectively relieve the symptoms such as anxiety, depression and the like of patients caused by gastrointestinal discomfort.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
A traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder comprises the following components in parts by weight: 15-20 parts of bupleurum, 15-20 parts of bighead atractylodes rhizome, 20-25 parts of dangshen, 10-15 parts of immature bitter orange, 15-20 parts of white paeony root, 10-15 parts of dried orange peel, 10-15 parts of ginger processed pinellia tuber, 10-15 parts of red sage root, 10-15 parts of villous amomum fruit and 10-15 parts of honey-fried licorice root.
Preferably, the composition comprises the following components in parts by weight: 18 parts of bupleurum, 18 parts of bighead atractylodes rhizome, 22 parts of codonopsis pilosula, 12 parts of immature bitter orange, 17 parts of white paeony root, 12 parts of dried orange peel, 12 parts of ginger processed pinellia tuber, 12 parts of red sage root, 12 parts of villous amomum fruit, and 12 parts of honey-fried licorice root.
Preferably, the composition comprises the following components in parts by weight: 20 parts of bupleurum, 20 parts of bighead atractylodes rhizome, 25 parts of radix codonopsis, 15 parts of immature bitter orange, 20 parts of white peony root, 15 parts of dried orange peel, 15 parts of ginger processed pinellia tuber, 15 parts of red sage root, 15 parts of fructus amomi, and 15 parts of honey-fried licorice root.
Preferably, the composition comprises the following components in parts by weight: 15 parts of bupleurum, 15 parts of bighead atractylodes rhizome, 20 parts of codonopsis pilosula, 10 parts of immature bitter orange, 15 parts of white peony root, 10 parts of dried orange peel, 10 parts of ginger processed pinellia tuber, 10 parts of red sage root, 10 parts of fructus amomi and 10 parts of honey-fried licorice root.
Preferably, adding pharmaceutically acceptable adjuvants, and making into one or more of decoction, granule, tablet, capsule, mixture, pill, powder, and powder.
Preferably, the preparation method of the granule, tablet or capsule comprises the following steps: weighing raw materials of the oral preparation, adding boiled water 6-10 times of the raw materials, and decocting for 2-3 times, each time for 1-2 hours; mixing the decoctions, concentrating under reduced pressure to obtain soft extract with relative density of 1.15-1.3, vacuum drying, pulverizing, sieving with 80-120 mesh sieve, adding appropriate amount of medicinal adjuvants according to specifications, granulating by dry method, tabletting or filling into capsule, and making into granule, tablet or capsule respectively.
Preferably, the preparation method of the mixture comprises the following steps: adding boiled water with the power of 6-10 times for 2-3 times, and each time for 1-2 hours; mixing the decoctions, adding appropriate amount of medicinal adjuvants according to specifications, adding Mel or sugar powder, and flavoring to obtain liquid mixture.
Preferably, the preparation method of the pill comprises the following steps: adding boiled water with the power of 6-8 times for 2-3 times, and each time for 1-2 hours; mixing the decoctions, concentrating under reduced pressure to obtain soft extract with relative density of 1.15-1.3, vacuum drying, pulverizing, sieving with 80-120 mesh sieve, adding appropriate amount of medicinal adjuvants according to specifications, making into pill with water or 15-30wt% ethanol, and making into pill.
Preferably, the medicine is taken 2 to 3 times a day and continuously treated for 2 to 4 weeks.
Compared with the prior art, the invention has the following beneficial effects:
1) The invention provides a traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder, which has the effects of soothing liver and strengthening spleen, regulating qi and regulating middle warmer, has good effects of improving symptoms such as epigastric pain and postprandial fullness, has good safety, and can effectively relieve symptoms such as anxiety, depression and the like of patients caused by gastrointestinal discomfort; the treatment group and the control group are lower than the treatment group before treatment and the treatment group is lower than the control group (P < 0.05); the NDI scores of the treatment group and the control group are improved compared with those of the treatment group before treatment, and the treatment group is superior to the control group (P is less than 0.05); the total score of both treatment and control PSQI was lower than before treatment, and the treatment was lower than control (P < 0.05); the total effective rate of the clinical symptoms of the treatment group and the control group is 86.84 percent and 69.23 percent respectively, and the treatment group is superior to the control group (P is less than 0.05).
2) The invention provides a traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder, which is prepared by adding bupleurum soothing liver powder, xiaojianzhong decoction and Xiangsha Liujunzi decoction, wherein bupleurum is a monarch drug and can sooth liver and relieve depression; the codonopsis pilosula is sweet in taste and flat in nature, has the effects of tonifying middle-jiao and Qi, nourishing blood and promoting the production of body fluid, and is a product for tonifying qi and blood; atractylodis rhizoma enters spleen and stomach channel, and has effects of invigorating spleen and replenishing qi, and yin and blood are autogenous; radix paeoniae alba can be used for regulating the interior and relieving urgency, softening liver and relieving pain; bitter orange is bitter and cold, is good at breaking qi and removing food retention to relieve distention and fullness, promoting qi circulation and removing food retention to relieve distention and fullness, and is adjunctive with dried orange peel and regulating qi and removing food retention, pinellia tuber and eliminating dampness and phlegm, and relieving distention and fullness and resolving masses; the red sage root enters the blood system, and has the effects of activating blood circulation to remove blood stasis and relieving pain; fructus Amomi is pungent and warm in nature, and has effects of promoting the circulation of qi, dispelling pathogenic heat, removing dampness, activating spleen, promoting the circulation of qi, and regulating middle warmer. The medicines are combined for use, and the effects of dispersing stagnated liver qi, invigorating spleen, regulating qi and regulating middle warmer are achieved.
Modern pharmacological researches indicate that the saikosaponin is the main component of bupleurum, wherein the saikosaponin A and the saikosaponin D have the highest content, and the main component of white paeony root is volatile oil, monoterpene, triterpene, flavonoid compound and the like, and both the saikosaponin and the saikosaponin can achieve the antidepressant effect by inhibiting the target point of the action of inflammatory factors in a monoamine transmitter system, thereby improving the insomnia anxiety state of patients. In addition, the paeonia lactiflora can improve the blood circulation of gastric mucosa, avoid the occurrence of smooth muscle spasm of the gastric body and keep the gastrointestinal function of a patient stable. The main chemical components of the largehead atractylodes rhizome volatile oil, the largehead atractylodes rhizome lactone, the largehead atractylodes rhizome polysaccharide and the like contained in the largehead atractylodes rhizome can regulate gastrointestinal functions and immune systems. Experiments for regulating intestinal flora of colonitis mice indicate that the codonopsis pilosula polysaccharide contained in codonopsis pilosula further acts on gastrointestinal tracts through decomposing into micromolecular substances, and the intestinal flora is recovered and the gastrointestinal functions are improved. The pericarpium Citri Tangerinae volatile oil has mild irritation to gastrointestinal tract, and has effects of promoting gastrointestinal tract inner qi accumulation and relieving gastrectasia symptom, and glycyrrhizic acid in radix Glycyrrhizae Preparata has antiinflammatory, liver injury resisting, cell immunity enhancing, and humoral immunity inhibiting effects. The effective component of fructus Aurantii Immaturus can promote intestinal peristalsis of zebra fish, wherein neohesperidin has optimal effect, thereby improving functional dyspepsia symptom. After rhizoma Pinelliae is processed by ginger, 6-gingerol is formed, the content of organic acid in chemical components is increased, the effect of warming middle warmer is obviously improved, and modern pharmacological experiments prove that the rhizoma Pinelliae processed by ginger has stronger effect of relieving cough and vomiting and resisting gastric ulcer, and effectively relieves the discomfort of PDS patients. The water-soluble component of the red sage root can promote gastric mucosa mucus secretion and synthesis of gastric mucosa cell DNA at the edge of ulcer, inhibit gastric motility and improve PDS clinical symptoms.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail with reference to the following examples. Of course, the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Unless otherwise specified, both chemical reagents and materials in the present invention are purchased through a market route or synthesized from raw materials purchased through a market route.
The medicines are provided by western pharmacies and traditional Chinese pharmacies in Nangang yard area of the academy of traditional Chinese medicine of the Heilongjiang province, and are decocted in the first generation by traditional Chinese pharmacies in Nangang yard area of the academy of traditional Chinese medicine of the Heilongjiang province to prepare the decoction.
The invention will be further illustrated by the following examples.
Example 1
A preparation method of a traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder comprises the following steps:
Weighing 15g of bupleurum, 15g of bighead atractylodes rhizome, 20g of codonopsis pilosula, 10g of immature bitter orange, 15g of white paeony root, 10g of dried orange peel, 10g of ginger processed pinellia tuber, 10g of red sage root, 10g of fructus amomi and 10g of honey-fried licorice root, and adding boiled water 10 times for 3 times, wherein each time is 1.5 hours; mixing the decoctions, concentrating under reduced pressure to obtain soft extract with relative density of 1.2, vacuum drying, pulverizing, sieving with 100 mesh sieve, adding appropriate amount of medicinal adjuvants according to specifications, and dry granulating to obtain Chinese medicinal composition for treating senile postprandial discomfort syndrome accompanied with sleep disorder.
The preparation is administered 3 times daily for 4 weeks.
Comparative example 1
The domperidone tablet (10 mg/time, orally 30min before meal) was taken 3 times daily for 4 weeks.
1. Clinical data
1.1 Diagnostic criteria
Western diagnosis meets Roman IV standards. The diagnosis of the traditional Chinese medicine accords with the spleen deficiency and qi stagnation differentiation standard in the consensus opinion of functional dyspepsia traditional Chinese medicine diagnosis and treatment specialist (2017).
1.2 Inclusion criteria
① Meets the diagnosis standards of the traditional Chinese medicine and the western medicine; ② PDS symptoms duration > 12 weeks; ③ Sleep disorders are secondary to PDS; ④ The ages are 60 to 80 years, and the clinical data are complete; ⑤ The patient and their family members all informed and consent, and signed an informed consent.
1.3 Exclusion criteria
① Combining the digestive system organic lesions such as peptic ulcer, gastritis, stomach tumor, etc.; ② Combining liver, heart, kidney, etc. with important viscera function deficiency; ③ The combined mental diseases are those with major depression, self-disabled and suicide tendencies; ④ Patients with serious operation and trauma history; ⑤ Primary sleep disorder and long-term administration of sleep improving drugs; ⑥ Poor compliance and inability to follow the prescribed treatment regimen.
1.4 Rejection criteria
① Other therapeutic agents (including sleep improving agents) are used in the clinic; ② And the patient does not take medicines according to the regulations or changes the medication scheme by himself in the observation process.
1.5 General data
80 Cases of spleen deficiency and qi stagnation type PDS senile patients with sleep disorder, which are treated in the senile disease outpatient service in Nangang hospital area of the Chinese medical science of Heilongjiang province, 9 months 2020-2022, are selected and classified into a control group and a treatment group by adopting a random digital table method. The study protocol was approved by the medical ethics committee of our hospital.
2. Observation index
2.1 Evaluation of curative effect of Chinese medical syndrome
The evaluation of the curative effect of the traditional Chinese medicine symptoms should be based on the characteristics of the main symptoms and the secondary symptoms of each symptom and the change rule of each symptom, and a more scientific symptom evaluation standard should be formulated. The main symptoms of the spleen deficiency and qi stagnation type postprandial discomfort syndrome are epigastric fullness, distending pain and anorexia, the secondary symptoms are belch, fatigue and loose stool, and each symptom is calculated according to a 4-level grading standard. See tables 1 and 2.
TABLE 1 spleen deficiency qi stagnation PDS Primary syndrome Condition scoring
TABLE 2 spleen deficiency qi stagnation PDS secondary syndrome condition score
2.2 Quality of life Nippon digestion index Scale (NDI)
NDI is a special scale of dyspepsia score, which comprises 4 aspects of sleep disturbance, cognitive control, diet and disturbance, and evaluates the influence of PDS on quality of life, and the higher the score, the better the quality of life.
2.3 Pittsburgh sleep quality index Meter (PSQI)
PSQI specifically includes 7 scoring factors, respectively: sleep quality, time to fall asleep, time to sleep, sleep efficiency, sleep disorders, hypnotics, and daytime dysfunction. Each factor is 0 to 3 minutes, and the total division is 0 to 21 minutes. The higher the score, the worse the sleep quality, the total score of more than 7 is divided into insomnia, 8-12 is mild insomnia, 13-17 is moderate insomnia, and 18-21 is severe insomnia. The hypnotic drug is not taken by the patient after clinical observation, so the score of the hypnotic drug is not counted into the total score, namely 0 to 18, the score of the estimated insomnia degree is correspondingly reduced by 3 scores, namely more than 4 scores are classified as insomnia, and the like.
3 Therapeutic efficacy criterion and statistical method
3.1 Efficacy assessment criteria
Calculated by nimodipine method. Efficacy index = (pre-treatment integral-post-treatment integral)/pre-treatment integral x 100%. The therapeutic effect determination criteria are shown in Table 3.
TABLE 3 therapeutic efficacy criterion
| Treatment efficacy determination | Principal symptoms and signs | Efficacy index |
| Invalidation of | No obvious improvement, even at home | <30％ |
| Effective and effective | Obviously improve | More than or equal to 30 percent and less than 70 percent |
| Has obvious effect | Obviously improve | More than or equal to 70 percent and less than 95 percent |
| Healing of the wound | Vanishing or substantially vanishing | ≥95％ |
Total effective rate = (number of clinical recovery cases + number of significant cases + number of effective cases)/total number of cases x 100%.
3.2 Statistical methods
Data statistical analysis was performed using SPSS20.0 statistical software to gauge dataRepresenting that the comparison between groups adopts two independent samples for t test; the comparison in the group adopts paired sample t test; count data is expressed as a percentage (%) using the x 2 test. P <0.05 is statistically significant for the differences.
Results 4 results
In the treatment process, 1 control group drops, 2 treatment groups drop, and finally 77 people incorporate the treatment effect observation statistics, wherein 39 control groups and 38 treatment groups. The comparison of the baseline data of group 2, the differences were statistically insignificant (P > 0.05), and comparable, as shown in Table 4.
Table 4 comparison of baseline data for two groups of patients
4.1 Comparison of clinical efficacy
The total clinical effective rate of the treatment group is 86.84 percent (33/38), the total clinical effective rate of the control group is 69.23 percent (27/39), and the treatment group is superior to the control group (P < 0.05). See table 5.
Table 52 clinical efficacy comparison of patients with spleen deficiency and qi stagnation PDS accompanied by sleep disorder in the elderly [ example (%)
| Group of | Number of examples | Has obvious effect | Effective and effective | Invalidation of | Is always effective |
| Treatment group | 38 | 22 | 11 | 5 | 33(86.84％)▲ |
| Control group | 39 | 18 | 9 | 12 | 27(69.23％) |
Note that: ▲ P < 0.05, compared to the control group.
4.2 Evaluation, integration and comparison of curative effects of traditional Chinese medicine syndromes
Before treatment, the traditional Chinese medicine symptoms of 2 groups of patients are evaluated, and each integral comparison is carried out, so that the difference has no statistical significance (P is more than 0.05). After treatment, the integral of each traditional Chinese medicine syndrome curative effect of each patient in the group 2 is reduced (P is less than 0.05) compared with that before treatment, the reduction amplitude of the treatment group is superior to that of the control group, and the difference has statistical significance (P is less than 0.05). See tables 6 and 7.
The traditional Chinese medicine syndrome integration comparison (divided into two parts) of the patients with spleen deficiency and qi stagnation PDS with sleep disorder before and after treatment of the patients with the senile spleen deficiency and qi stagnation PDS with sleep disorder is carried out on the group 62,)
Note that: ▲ P < 0.05, compared to the pre-treatment group; ◆ P < 0.05, and is compared with the control group in the same period.
The traditional Chinese medicine syndrome integral comparison (divided into two parts) of the patients with the spleen deficiency and qi stagnation PDS with the sleep disorder before and after the treatment of the patients with the senile spleen deficiency and qi stagnation PDS with the sleep disorder are shown in the Table 72,)
Note that: p < 0.05, compared to the pre-treatment group; p < 0.05, and is compared with the control group in the same period.
4.3 Comparison of the grade of the dyspepsia index (NDI)
The differences were statistically significant (P > 0.05) by comparison of NDI scores of the 2 groups of patients prior to treatment. After treatment, the NDI integral of 2 groups of patients is increased (P is less than 0.05) compared with that before treatment, the variation amplitude of the NDI integral of the treatment group is obviously superior to that of a control group, and the differences are statistically significant (P is less than 0.05). See table 8.
Table 82 comparison of NDI scores before and after treatment of aged spleen deficiency qi stagnation PDS with sleep disorder patients (score,)
Note that: ▲ P < 0.05, compared to the pre-treatment group; ◆ P < 0.05, and is compared with the control group in the same period.
4.4 Comparison of Pittsburgh sleep quality index Scale (PSQI)
Prior to treatment, the differences were statistically significant (P > 0.05) in the PSQI integrated comparisons of the 2 groups of patients. After treatment, the PSQI scores were all lower in the 2 groups compared to the pre-treatment (P < 0.05) and the total score in the treatment group PSQI was lower than in the control group (P < 0.05). See table 9.
Table 9 2 group of senile spleen deficiency qi stagnation PDS with sleep disorder patients before and after treatment pittsburgh sleep quality index scale score comparison (score,)
Note that: ▲ P < 0.05, compared to the pre-treatment group; ◆ P < 0.05, and is compared with the control group in the same period.
4.5 Evaluation of safety
During the treatment period, no obvious adverse reaction occurs to the patients in the group 2, and the safety is high.
The foregoing is only a preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art, who is within the scope of the present invention, should make equivalent substitutions or modifications according to the technical scheme of the present invention and the inventive concept thereof, and should be covered by the scope of the present invention.
Claims (9)
1. A traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder is characterized by comprising the following components in parts by weight: 15-20 parts of bupleurum, 15-20 parts of bighead atractylodes rhizome, 20-25 parts of dangshen, 10-15 parts of immature bitter orange, 15-20 parts of white paeony root, 10-15 parts of dried orange peel, 10-15 parts of ginger processed pinellia tuber, 10-15 parts of red sage root, 10-15 parts of villous amomum fruit and 10-15 parts of honey-fried licorice root.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in parts by weight: 18 parts of bupleurum, 18 parts of bighead atractylodes rhizome, 22 parts of codonopsis pilosula, 12 parts of immature bitter orange, 17 parts of white paeony root, 12 parts of dried orange peel, 12 parts of ginger processed pinellia tuber, 12 parts of red sage root, 12 parts of villous amomum fruit, and 12 parts of honey-fried licorice root.
3. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in parts by weight: 20 parts of bupleurum, 20 parts of bighead atractylodes rhizome, 25 parts of radix codonopsis, 15 parts of immature bitter orange, 20 parts of white peony root, 15 parts of dried orange peel, 15 parts of ginger processed pinellia tuber, 15 parts of red sage root, 15 parts of fructus amomi, and 15 parts of honey-fried licorice root.
4. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in parts by weight: 15 parts of bupleurum, 15 parts of bighead atractylodes rhizome, 20 parts of codonopsis pilosula, 10 parts of immature bitter orange, 15 parts of white peony root, 10 parts of dried orange peel, 10 parts of ginger processed pinellia tuber, 10 parts of red sage root, 10 parts of fructus amomi and 10 parts of honey-fried licorice root.
5. The composition of any one of claims 1-4, wherein the composition is formulated into one or more of a decoction, a granule, a tablet, a capsule, a mixture, a pill, a powder, and a powder by adding pharmaceutically acceptable excipients.
6. The Chinese medicinal composition according to claim 5, wherein the preparation method of the granule, tablet or capsule comprises the following steps: weighing raw materials of the oral preparation, adding boiled water 6-10 times of the raw materials, and decocting for 2-3 times, each time for 1-2 hours; mixing the decoctions, concentrating under reduced pressure to obtain soft extract with relative density of 1.15-1.3, vacuum drying, pulverizing, sieving with 80-120 mesh sieve, adding appropriate amount of medicinal adjuvants according to specifications, granulating by dry method, tabletting or filling into capsule, and making into granule, tablet or capsule respectively.
7. The Chinese medicinal composition according to claim 5, wherein the preparation method of the mixture comprises the following steps: adding boiled water with the power of 6-10 times for 2-3 times, and each time for 1-2 hours; mixing the decoctions, adding appropriate amount of medicinal adjuvants according to specifications, adding Mel or sugar powder, and flavoring to obtain liquid mixture.
8. The Chinese medicinal composition of claim 5, wherein the preparation method of the pill comprises the following steps: adding boiled water with the power of 6-8 times for 2-3 times, and each time for 1-2 hours; mixing the decoctions, concentrating under reduced pressure to obtain soft extract with relative density of 1.15-1.3, vacuum drying, pulverizing, sieving with 80-120 mesh sieve, adding appropriate amount of medicinal adjuvants according to specifications, making into pill with water or 15-30wt% ethanol, and making into pill.
9. The Chinese medicinal composition according to claim 1, wherein the administration is carried out 2 to 3 times daily for 2 to 4 weeks.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410248079.3A CN118021915A (en) | 2024-03-05 | 2024-03-05 | Traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410248079.3A CN118021915A (en) | 2024-03-05 | 2024-03-05 | Traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118021915A true CN118021915A (en) | 2024-05-14 |
Family
ID=90994763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410248079.3A Pending CN118021915A (en) | 2024-03-05 | 2024-03-05 | Traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118021915A (en) |
-
2024
- 2024-03-05 CN CN202410248079.3A patent/CN118021915A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102274448B (en) | Pharmaceutical composition for treating spleen deficiency and qi stagnation type functional dyspepsia and preparation method | |
| CN103656535B (en) | A kind of Chinese medicine composition for the treatment of hyperlipemia and preparation method thereof | |
| CN110833609A (en) | Traditional Chinese medicine composition for treating dyspepsia | |
| CN102274479B (en) | Traditional Chinese medicine composition for treating functional dyspepsia | |
| CN102302758B (en) | Pharmaceutical composition for treating functional dyspepsia (FD) based on intermingled cold and heat symptom and preparation method thereof | |
| CN101757281A (en) | Traditional Chinese medicine composition for treating gastrointestinal disease and preparation method thereof | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN105012770A (en) | Health drink and preparation method thereof | |
| CN103830653A (en) | Pure traditional Chinese medicine preparation for treating infantile persistent diarrhea and preparation method thereof | |
| CN101468097B (en) | Chinese medicinal composition for nourishing liver and kidney, moistening intestines and relaxing piss, preparation and method for preparing the same | |
| CN118021915A (en) | Traditional Chinese medicine composition for treating senile postprandial discomfort syndrome and sleep disorder | |
| CN105920517B (en) | A kind of Radix Glycyrrhizae complex composition of clear throat | |
| CN111249381A (en) | Application of composition in preparation of medicine for preventing and treating constipation | |
| CN104857414A (en) | Medicine composite for treating chronic simple rhinitis | |
| CN104510937A (en) | Traditional Chinese medicinal formula for treating infantile asthma and preparation method for paste of traditional Chinese medicinal formula | |
| CN116350741B (en) | Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof | |
| CN116763880B (en) | Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation | |
| CN116059302B (en) | Traditional Chinese medicine composition for treating gastrointestinal motility diseases and preparation method and application thereof | |
| CN115869375B (en) | Traditional Chinese medicine composition for clearing heat and dispelling wind as well as preparation method and application thereof | |
| CN105748937A (en) | Traditional Chinese medicine composition for postoperative rehabilitation of differentiated thyroid carcinoma | |
| CN105456499A (en) | Traditional Chinese medicine preparation for treating constipation and preparation method | |
| CN105796886A (en) | Pharmaceutical composition capable of treating chronic constipation | |
| CN117838805A (en) | Special formula for cold-dryness cold and preparation method thereof | |
| CN117462641A (en) | Chinese medicinal composition for treating AIDS-related herpes zoster and Chinese medicinal preparation thereof | |
| CN103830640A (en) | Traditional Chinese medicine oral liquid and sore throat relieving tablets for treating chronic pharyngitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |